Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Hepregen Launches First Dual-Species HepatoPac™ DMPK Assay Kits

Published: Wednesday, September 25, 2013
Last Updated: Tuesday, September 24, 2013
Bookmark and Share
Rat and human liver cells on a single tissue culture plate designed for high efficiency data collection.

Hepregen Corporation has announced the commercial launch of the Company's first application-oriented, dual-species HepatoPac™ kit designed specifically for use in metabolite identification and profiling.

Each kit contains one standard 24-well tissue culture plate, half containing micro-patterned human hepatocytes, and the other half containing micro-patterned rat hepatocytes (available in Wistar-Hahn or Sprague-Dawley strains).

The hepatocytes on these plates from both species remain fully functional for up to two months. These unique dual-species kits provide customers with a plug-in-ready product, designed for use in evaluating metabolite production in a discovery or development setting, or in any case where a quick comparative answer is beneficial.

Dr. Vincent Zurawski, Hepregen's chief executive officer stated, "The incredible flexibility of our HepatoPac™ assay systems allows Hepregen to provide customers with a variety of cost-effective options for generating predictive and mechanistic data regarding metabolite identification and profiling."

He added, "The launch of this new dual-species product represents another way in which Hepregen is responding to customer needs. Data collected from two species simultaneously in a single experiment, especially when one or just a few compounds need to be evaluated rapidly, provides the highest efficiency approach to predicting likely in vivo metabolic outcomes in the laboratory."

Jack McGeehan, Hepregen's vice president of operations, added, "Our new dual-species product is a perfect fit for both smaller pharmaceutical companies that are testing a limited number of compounds, or DMPK groups within larger companies who support program teams in need of quick answers to questions regarding likely best approaches to preclinical evaluation. Our new HepatoPac™ kit can provide answers that will support clinical trial design or approaches to toxicokinetic testing."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QTS and Hepregen Execute Co-Development and Co-Marketing Agreement
Agreement provides for development, manufacture and sale of HepatoPac® B-CLEAR® co-labeled proprietary products for liver transporter analysis.
Tuesday, November 04, 2014
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!